A Study to Learn What Participants Think of Treatment With Betamethasone Plus Loratadine to Treat Their Acute Allergic Rhinitis, Also Known as Hay Fever in Mexico
The Perception of Celestamine Treatment in Mexico: a Retrospective Assessment of Consumer Perception of Prior Celestamine Use
1 other identifier
observational
153
1 country
1
Brief Summary
Acute allergic rhinitis is a common allergic reaction to things like pollen or dust. It causes inflammation inside the nose, resulting in symptoms similar to the common cold. Allergic rhinitis is also known as hay fever. In this study, the researchers want to learn what participants think of betamethasone plus loratadine as a treatment for their acute allergic rhinitis. These participants will have used betamethasone plus loratadine as a treatment for their acute allergic rhinitis within the past two months. During the study, participants will complete an online questionnaire about their experience with betamethasone plus loratadine.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 11, 2020
CompletedFirst Submitted
Initial submission to the registry
November 23, 2020
CompletedFirst Posted
Study publicly available on registry
November 27, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 27, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
November 27, 2020
CompletedJune 1, 2023
May 1, 2023
16 days
November 23, 2020
May 31, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Experience with betamethasone plus loratadine via an online questionnaire
Participants' experiences with betamethasone plus loratadine used under real life conditions.
2 months
Study Arms (1)
Participants
Participants who used betamethasone plus loratadine to treat allergic rhinitis within the previous two months.
Interventions
Participants will be invited to complete an online questionnaire about their experience of product use.
Eligibility Criteria
The study population are participants who used betamethasone plus loratadine within the previous 2 months for the treatment of acute episodes of allergic rhinitis.
You may qualify if:
- Participants who used betamethasone plus loratadine within the previous 2 months for the treatment of acute episodes of allergic rhinitis
- Participants allowing to use the data for research and marketing purposes as well as talking to authorities
- Participants allowing us to use the pseudo-randomized individual data for further data analysis
- Able to read and understand the language of the online questionnaire
You may not qualify if:
- \- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Bayerlead
Study Sites (1)
Many locations
Multiple Locations, Mexico
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 23, 2020
First Posted
November 27, 2020
Study Start
November 11, 2020
Primary Completion
November 27, 2020
Study Completion
November 27, 2020
Last Updated
June 1, 2023
Record last verified: 2023-05
Data Sharing
- IPD Sharing
- Will not share
Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.